Expert Panel to Demonstrate DABRA Clinical Outcomes via Live Cases and Symposium at C3
June 21 2019 - 10:09AM
Business Wire
Ra Medical Systems, Inc. (NYSE: RMED) announced two live cases
and an expert panel presentation of clinical outcomes utilizing
DABRA for the treatment of peripheral artery disease (PAD) to occur
at the C3 Global Summit.
"The DABRA excimer laser is a new technology which has added
significant capability and options for our complex vascular
patients,” said Rajesh M. Dave, MD. “In my practice, DABRA has
delivered successful outcomes, has proven to be safe with no
reported cases of distal embolization, and is effective in
dissolving variety of plaque types.” Dr. Dave is Chairman of the
Department of Cardiology, Geisinger Holy Spirit Hospital in Camp
Hill, PA. He is also Chairman of the C3 Global Summit and Study
Chairman of the DABRA RESULTS registry study.
The schedule of Ra Medical events is as follows:
- Expert panel symposium, Monday, June
24 at 10:30 a.m. in Salon
BC as part of the endovascular track, featuring:
- Mohammad Ansari, MD
- Rajesh M. Dave, MD
- Ashok Kondur, MD
- Live case transmissions Monday, June
24:
- 11:00 am EDT Charles Bailey, MD, Heart Endovascular and Rhythm
of Texas
- 2:05 pm EDT Athar Ansari, MD, California Heart & Vascular
Clinic
DABRA (Destruction of Arteriosclerotic Blockages by laser
Radiation Ablation) is a novel, minimally invasive excimer laser
system that non-thermally, photochemically ablates channels in
vascular blockages. Unlike many mechanical, acoustic, or thermal
treatments for PAD that may damage the arterial wall, DABRA
dissolves blockages with minimal vascular trauma.
“By offering a safe and highly effective treatment for patients
with PAD, the DABRA laser is helping physicians save the limbs and
lives of their patients throughout the world,” said Dean Irwin,
CEO, Ra Medical Systems.
The Complex Cardiovascular Catheter Therapeutics (C3): Advanced
Endovascular and Coronary Intervention Global Summit conference
takes place from June 23 – 26 in Orlando, FL. C3 has been designed
for physicians who specialize in interventional cardiology,
vascular surgery, interventional radiology, podiatry, as well as
fellows, residents, and other healthcare professionals interested
in atherosclerotic cardiovascular disease. For more information,
please visit Ra Medical Systems at Booth No. 206 at C3 or visit
www.ramed.com.
About Ra Medical Systems
Ra Medical Systems is a commercial medical device company
developing and marketing innovative excimer laser systems for the
treatment of vascular and dermatologic diseases. DABRA launched in
2017 for the endovascular treatment of blockages resulting from
lower extremity vascular disease. Pharos launched in 2004 for the
treatment of dermatological disorders including psoriasis,
vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra
Medical’s core excimer laser technology platform that produces 308
nanometer light, a UVB wavelength that studies have demonstrated
increases T-cell apoptosis, or cell death, which may produce a
beneficial, targeted immunosuppressive effect. Ra Medical
manufactures DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is
licensed by the state of California to manufacture sterile,
single-use catheters in controlled environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical's future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as "may," "will," "should," "expects," "plans,"
"anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these words or other similar terms or
expressions that concern Ra Medical's future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential benefits to patients and physicians using the DABRA
catheter and laser system. Ra Medical's expectations and beliefs
regarding these matters may not materialize, and actual results in
future periods are subject to risks and uncertainties that could
cause actual results to differ materially from those projected or
implied by such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of DABRA and Pharos and procedures performed using such devices by
physicians, payors, and other third parties; development and
acceptance of new products or product enhancements; clinical and
statistical verification of the benefits achieved via the use of Ra
Medical’s products; the Company’s ability to effectually manage
inventory; Ra Medical’s ability to recruit and retain management
and key personnel; Ra Medical’s need to comply with complex and
evolving laws and regulations; intense and increasing competition
and consolidation in Ra Medical’s industry; the impact of rapid
technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory
inspections; and the other risks and uncertainties described in Ra
Medical’s news releases and filings with the Securities and
Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical's
business and operating results is contained in Ra Medical’s
quarterly report on Form 10-Q for the quarter ended March 31, 2019
and in its other filings with the Securities and Exchange
Commission. The forward-looking statements in this press release
are based on information available to Ra Medical as of the date
hereof, and Ra Medical disclaims any obligation to update any
forward-looking statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings, and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190621005298/en/
Media Contacts Dave Schemelia / Lisa Lipson KCSA
Strategic Communications 212.896.1242 / 508-843-6428
dschemelia@kcsa.com / llipson@comcast.net
Investor Contact Jeffrey Kraws President, Ra Medical
Systems 760.707.7516 investorrelations@ramed.com
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Sep 2023 to Sep 2024